AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma treatment Fasenra.

People with severe asthma insured by BlueCross BlueShield of Illinois may soon face a new hurdle in accessing a treatment ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Blue Cross Blue Shield of Texas will stop covering certain asthma infusion treatments in clinics, obliging patients to self-inject the drugs at home. The provider will cut this coverage from its plans ...

Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used ...

Blue Cross Blue Shield of Oklahoma (BCBS), including BCBS plans in states of Illinois, New Mexico, Texas and Montana, is ...

AstraZeneca Stock Performance Shares of AstraZeneca stock opened at $76.32 on Thursday. The company has a 50 day moving average price of $72.47 and a 200 day moving average price of $72.16. The ...

Wealthfront Advisers LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange ...